Angelica LaVito

Stay informed with Angelica LaVito’s coverage and analysis for Fortune.

  • Researchers continue to puzzle over why the COVID vaccine developed by AstraZeneca and Oxford University appears to be more effective on a half dose. Wire photography: Lisa Maree Williams—Getty ImagesHealth

    For AstraZeneca’s COVID vaccine, less may be more—and that’s puzzling researchers

    By Angelica LaVito, John Lauerman, and others
  • Walgreens has hired a new CEO.Finance

    Walgreens hires John Standley, former Rite Aid CEO, to run U.S. unit

    By Bloomberg and Angelica LaVito
  • TOPSHOT-US-HEALTH-VIRUS-VACCINE-TRIALSHealth

    U.S. will conduct an unofficial dry run of a COVID-19 vaccine campaign this fall

    By John Tozzi, Angelica LaVito, and others
  • A woman submits to a common coronavirus test, using a swab. Companies are inconsistent in their practice of testing employees for COVID-19.Health

    The great workplace testing dilemma—Why some companies are screening employees for COVID-19, while others have opted out

    By Emma Court, Christopher Palmeri, and others
  • Young people are getting sick from coronavirus.Health

    Young people are getting extremely sick from coronavirus, according to new evidence

    By Michelle Cortez, Angelica LaVito, and others
  • James Monsees-JuulFinance

    Juul co-founder James Monsees steps down as adviser, board member

    By Angelica LaVito and Bloomberg
  • Altria writes down Juul stake by 1/3Finance

    Altria drastically distances itself from Juul after writedown

    By Tiffany Kary, Angelica LaVito, and others